Clinical Trial Update: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC [Phase 1, Phase 2]

View source ↗

Summary

Lisata Therapeutics reports that the Phase 1b/2a continuous infusion trial of ceretpetide in pancreatic ductal adenocarcinoma has been withdrawn. The study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Certepetide (certepetide)

Snippet

Sponsor: Lisata Therapeutics, Inc. | Conditions: Pancreas Cancer, Pancreatic Carcinoma | Phase 1, Phase 2 | Status: WITHDRAWN